<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS141212</article-id>
<article-id pub-id-type="doi">10.1101/2021.12.27.474307</article-id>
<article-id pub-id-type="archive">PPR436910</article-id>
<article-version article-version-type="publisher-id">1</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Zhou</surname>
<given-names>Tongqing</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="fn" rid="FN1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Lingshu</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="fn" rid="FN1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Misasi</surname>
<given-names>John</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
<xref ref-type="fn" rid="FN1">#</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Pegu</surname>
<given-names>Amarendra</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Yi</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Harris</surname>
<given-names>Darcy R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Olia</surname>
<given-names>Adam S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Talana</surname>
<given-names>Chloe Adrienna</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Yang</surname>
<given-names>Eun Sung</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Chen</surname>
<given-names>Man</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Choe</surname>
<given-names>Misook</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Wei</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Teng</surname>
<given-names>I-Ting</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Creanga</surname>
<given-names>Adrian</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Jenkins</surname>
<given-names>Claudia</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Leung</surname>
<given-names>Kwanyee</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Liu</surname>
<given-names>Tracy</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stancofski</surname>
<given-names>Erik-Stephane D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Stephens</surname>
<given-names>Tyler</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Baoshan</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Tsybovsky</surname>
<given-names>Yaroslav</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Graham</surname>
<given-names>Barney S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Mascola</surname>
<given-names>John R.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="fn" rid="FN2">^</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Sullivan</surname>
<given-names>Nancy J.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="fn" rid="FN2">^</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Kwong</surname>
<given-names>Peter D.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">*</xref>
<xref ref-type="fn" rid="FN2">^</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA</aff>
<aff id="A2">
<label>2</label>Electron Microscopy Laboratory, Cancer Research Technology Program, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD 21702, USA</aff>
<author-notes>
<corresp id="CR1">
<label>*</label>
<bold>Corresponding authors:</bold> John Misasi: <email>john.misasi@nih.gov</email>; Peter D. Kwong: <email>pdkwong@nih.gov</email>
</corresp>
<fn id="FN1" fn-type="equal">
<label>#</label>
<p id="P1">Equal contribution</p>
</fn>
<fn id="FN2" fn-type="equal">
<label>^</label>
<p id="P2">Equal contribution</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>07</day>
<month>02</month>
<year>2022</year>
</pub-date>
<pub-date pub-type="preprint">
<day>28</day>
<month>12</month>
<year>2021</year>
</pub-date>
<permissions>
<ali:free_to_read/>
<license>
<ali:license_ref>https://creativecommons.org/publicdomain/zero/1.0/</ali:license_ref>
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/publicdomain/zero/1.0/">CC0 license</ext-link>.</license-p>
</license>
</permissions>
<abstract>
<p id="P3">With B.1.1.529 SARS-CoV-2 variant’s rapid spread and substantially increased resistance to neutralization by vaccinee and convalescent sera, monoclonal antibodies with potent neutralization are eagerly sought. To provide insight into effective neutralization, we determined cryo-EM structures and evaluated potent receptor-binding domain (RBD) antibodies for their ability to bind and neutralize this new variant. B.1.1.529 RBD mutations altered 16% of the RBD surface, clustering on a ridge of this domain proximal to the ACE2-binding surface and reducing binding of most antibodies. Significant inhibitory activity was retained, however, by select monoclonal antibodies including A19-58.1, B1-182.1, COV2-2196, S2E12, A19-46.1, S309 and LY-CoV1404, which accommodated these changes and neutralized B.1.1.529 with IC<sub>50</sub>s between 5.1-281 ng/ml, and we identified combinations of antibodies with potent synergistic neutralization. Structure-function analyses delineated the impact of resistance mutations and revealed structural mechanisms for maintenance of potent neutralization against emerging variants.</p>
</abstract>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P4">Since first appearing in late 2019 (<xref ref-type="bibr" rid="R1">1</xref>), SARS-CoV-2 has infected over 280 million people and resulted in over 5.4 million deaths (<xref ref-type="bibr" rid="R2">2</xref>). In the summer of 2020 when the B.1.1.7 (Alpha) variant was first reported, it became apparent that host-virus interactions and virus adaption to immune pressures were leading to the generation of variants with variable pathogenicity, transmissibility and increasingly, the ability to escape from vaccines and therapeutic antibody treatments. The appearance and rapid spread of the B.1.1.529 (Omicron) variant (<xref ref-type="bibr" rid="R3">3</xref>, <xref ref-type="bibr" rid="R4">4</xref>), with almost 40 mutations in spike, three times higher than the number found in prior variants, has raised alarm. How do these mutations impact spike? How do they alter recognition by antibody? And can potent neutralization be maintained? While extremely broad antibodies such as S2P6 (<xref ref-type="bibr" rid="R5">5</xref>) have been identified that neutralize diverse beta-coronaviruses including SARS-CoV-2 and are likely to be unencumbered by B.1.1.529 mutations, these broad antibodies neutralize in the microgram per ml range, whereas current therapeutic antibodies generally neutralize ~100-times more potently, in the 1-50 nanogram per ml range for the ancestral D614G virus. In this study, we determine cryo-EM structures of the B.1.1.529 spike, measure the binding and neutralization capacity of leading monoclonal antibodies against five variants of concern (VOC), including B.1.1.529, and use functional and structural analyses to determine the bases for differences in variant neutralization and to identify antibodies and combinations of antibodies capable of potently neutralizing emerging variants including B.1.1.529.</p>
<sec id="S2">
<title>Cryo-EM structure of B.1.1.529 (Omicron) spike</title>
<p id="P5">To provide insight into the impact of B.1.1.529 mutations on spike, we expressed and produced the two proline-stabilized (S2P) (<xref ref-type="bibr" rid="R6">6</xref>) B.1.1.529 spike and collected single particle cryo-EM data to obtain a structure of the trimeric ectodomain at 3.29 Å resolution (<xref ref-type="fig" rid="F1">Fig. 1A</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S1, Fig S2 and Table S1</xref>). Like other D614G containing variants, the most prevalent spike conformation comprised the single-receptor-binding domain (RBD)-up conformation (<xref ref-type="bibr" rid="R7">7</xref>). B.1.1.529 mutations present in the spike gene resulted in 3 deletions of 2, 3 and 1 amino acids, a single insertion of 3 amino acids and 30 amino acid substitutions in the spike ectodomain. As expected from the ~3% variation in sequence, the B.1.1.529 spike structure was extremely similar to the WA-1 spike structure with an overall Cα-backbone RMSD of 1.8 Å (0.5 Å for the S2 region); however, we did observe minor conformational changes in a few places. For example, the RBD S371L/S373P/S375F substitutions changed the conformation of their residing loop, with Phe375 in the RBD-up protomer formed Phe-Phe interaction with Phe486 in the neighboring RBD-down protomer (<xref ref-type="fig" rid="F1">Fig. 1B</xref>), helping to stabilize the single-RBD-up conformation. Amino acid changes were denser in the N-terminal domain (NTD) and RBD, where a majority of neutralization occurs, though RMSDs remained low (0.6 Å and 1.2 Å for NTD and RBD, respectively). Notably, about half the B.1.1.529 alterations in sequence outside NTD and RBD involved new interactions, both hydrophobic, such as Tyr796 with glycan on Asn709, and electrostatic, such as Lys547 and Lys856 interacting with residues in HR1 SD1 on neighboring protomers (<xref ref-type="fig" rid="F1">Fig. 1B</xref>, <xref ref-type="supplementary-material" rid="SD1">Table S2</xref>). These heightened interprotomer interactions suggested a need to maintain trimer stability. Differential scanning calorimetry indicated the B.1.1.529 spike to have folding energy similar to the original WA-1 strain (<xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>).</p>
<p id="P6">NTD changes altered ~6% of the solvent accessible surface on this domain, and several were located directly on or proximal to the NTD-supersite of vulnerability (<xref ref-type="bibr" rid="R8">8</xref>), where prior variants had mutations that substantially reduced neutralization by NTD antibodies. Other NTD changes were proximal to a pocket, proposed to be the site of bilirubin binding (<xref ref-type="bibr" rid="R9">9</xref>), which also binds antibody (<xref ref-type="bibr" rid="R10">10</xref>) (<xref ref-type="fig" rid="F1">Fig. 1C</xref>).</p>
<p id="P7">RBD alterations changed ~16% of the solvent accessible surface on this domain and were constrained to the outward facing ridge of the domain (<xref ref-type="fig" rid="F1">Fig. 1D</xref>), covering much of the surface of the trimeric spike apex (<xref ref-type="supplementary-material" rid="SD1">Fig. S1F</xref>). Several amino acid changes involved basic substitutions, resulting in a substantial increase in RBD electro-positivity (<xref ref-type="fig" rid="F1">Fig. 1D</xref>). Overall, RBD changes were located proximal to binding surfaces for the ACE2 receptor (<xref ref-type="bibr" rid="R11">11</xref>) (<xref ref-type="fig" rid="F1">Fig. 1D</xref>) as well as to recognition sites for potently neutralizing antibodies (<xref ref-type="fig" rid="F1">Fig. 1E</xref>) (<xref ref-type="bibr" rid="R12">12</xref>–<xref ref-type="bibr" rid="R14">14</xref>).</p>
</sec>
<sec id="S3">
<title>Functional assessment of variant binding to ACE2</title>
<p id="P8">When pathogens infect a new species, sustained transmission leads to adaptations that optimize replication, immune-avoidance and transmission. One hypothesis for the efficient species adaptation and transmission of SARS-CoV-2 in humans is that the virus spikes are evolving to optimize binding to the host receptor protein, ACE2. As a first test of this hypothesis, we used a flow cytometric assay to evaluate binding of human ACE2 to cells expressing variant spike proteins. We evaluated the binding of soluble dimeric ACE2 to B.1.1.7 (<xref ref-type="bibr" rid="R15">15</xref>), B.1.351 (Beta) (<xref ref-type="bibr" rid="R16">16</xref>), P.1 (Gamma) (<xref ref-type="bibr" rid="R17">17</xref>, <xref ref-type="bibr" rid="R18">18</xref>) or B.1.617.2 (Delta) (<xref ref-type="bibr" rid="R19">19</xref>) spikes compared to the ancestral D614G spike. The earliest variants, B.1.1.7, B.1.351 and P.1, first recognized in December 2020 and January 2021 contain an RBD mutation at N501Y, which has been proposed to increase binding to ACE2 (<xref ref-type="bibr" rid="R20">20</xref>). Cell surface ACE2 binding to B.1.1.7 was 124% of D614G, while B.1.351, and P.1 were 69% and 76%, respectively (<xref ref-type="supplementary-material" rid="SD1">Fig S3A</xref>), demonstrating that these variants do not have a substantial increase in ACE2 affinity. We next evaluated binding to the B.1.1.529 spike protein and observed ACE2 binding to be 200% that of D614G variant (<xref ref-type="supplementary-material" rid="SD1">Fig S3A</xref>).</p>
<p id="P9">Since cell-surface binding may involve other factors, such as might be impacted by the increased electro-positivity of the RBD noted above, and formal kinetic measurements are challenging to obtain using cell-based assays, we further investigated ACE2 binding affinity using surface plasmon resonance measurements of soluble dimeric human ACE2 to S2P spike trimers generated from the ancestral WA-1 and 6 subsequent variants: D614G, B.1.351, P.1, B.1.617.2, B.1.1.7 and B.1.1.529. We observed that both WA-1 and D614G, which have identical RBD sequences, have similar affinities (<italic>K<sub>D</sub>
</italic>= 1.1 nM and 0.73 nM, respectively) (<xref ref-type="supplementary-material" rid="SD1">Fig S3B, C</xref>). We noted that the affinity for B.1.617.2, which contains two RBD mutations, was ~3-fold worse (KD=2.4 nM) than the D614G S2P trimer. We next evaluated B.1.1.7, B.1.351, P.1 and B.1.1.529, which each contain N501Y substitutions, and found affinities of 0.59 nM, 1.7 nM, 0.85 nM and 3.8 nM, respectively (<xref ref-type="supplementary-material" rid="SD1">Fig S3B,C</xref>). Collectively, the cell surface and S2P binding results show minimal improved affinity in some, but not all spikes, and suggests that, while SARS-CoV-2 maintains nanomolar affinity to ACE2, spike variant evolution appears to be driven primarily by immune pressure.</p>
</sec>
<sec id="S4">
<title>Variant binding and neutralization by individual monoclonal antibodies</title>
<p id="P10">To define of the impact SARS CoV-2 variant amino acid changes on the binding and neutralization of monoclonal antibodies, we expressed and purified 17 highly potent antibodies targeting the spike RBD (<xref ref-type="bibr" rid="R12">12</xref>, <xref ref-type="bibr" rid="R13">13</xref>, <xref ref-type="bibr" rid="R21">21</xref>–<xref ref-type="bibr" rid="R33">33</xref>)<italic>;</italic> including 13 antibodies currently under clinical investigation or approved for use under expanded use authorization (EUA) by the United States Food and Drug Administration. All antibodies bound and neutralized B.1.1.7 comparable to the ancestral D614G and consistent with the single 501Y substitution being outside each antibody’s binding epitope (<xref ref-type="fig" rid="F2">Fig 2</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S4A</xref>). The addition of two more RBD substitutions, K417N and E484K (<xref ref-type="fig" rid="F2">Fig 2A</xref>) in the B.1.351 and P1 variants eliminated binding by two Class I antibodies, CB6 and REGN10933 and two Class II antibodies, LY-CoV555 and C144 (<xref ref-type="fig" rid="F2">Fig 2B</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S4A</xref>). Neutralization of B.1.351 and P1 by CB6, LY-CoV555 and C144 was completely abolished, while REGN10933 was eliminated for B.1.351 and reduced &gt;250-fold for P.1. In addition, while binding of CT-P59 to B.1.351 and P.1 variants was minimally changed (69-79%), neutralization was decreased 26-43-fold (IC<sub>50</sub> 65.8 and 39.6 ng/mL) (<xref ref-type="fig" rid="F2">Fig 2B,C</xref>). The remaining antibodies showed minimal binding changes and a &lt;3.6-fold difference in neutralization IC<sub>50</sub> (<xref ref-type="fig" rid="F2">Fig 2B,C</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig S4A</xref>). An evaluation of the antibodies in our panel against B.1.617.2 revealed minimal changes in binding for all antibodies except A19-46.1 and LY-CoV555, which were 0% of D614G (<xref ref-type="fig" rid="F2">Fig 2B</xref>). Neutralization assays using B.1.617.2 pseudovirus showed that the REGN10987 IC<sub>50</sub> was 22.7-fold lower than D614G and neutralization values for A19-46.1 and LY-CoV555 were each &gt;10,000 ng/mL (<xref ref-type="fig" rid="F2">Fig 2C</xref>). These data are consistent with previous results that showed both A19-46.1 and LY-CoV555 were sensitive to the L452R mutations present in B.1.617.2 (<xref ref-type="bibr" rid="R14">14</xref>).</p>
<p id="P11">For B.1.1.529, we noted that all but three antibodies showed binding less than 31% of D614G. It is interesting to note that COV2-2196, S2E12, B1-182.1 and A23-58.1 utilize the same VH1-58 gene in their heavy chain and target a similar region on the RBD (i.e., VH1-58 supersite), but show differential binding to the B.1.1.529 (<italic>i.e.,</italic> 4%, 5%, 8% and 11%, respectively) and B.1.617.2 (<italic>i.e.,</italic> 66%, 67%, 77% and 85%, respectively) (<xref ref-type="fig" rid="F2">Fig 2B</xref>). Even though the absolute differences in binding are minimal, the shared trend may be reflective of how the RBD tip mutation at T478K mutation is accommodated by each of these antibodies. Finally, LY-CoV1404 revealed 61% binding to B.1.1.529 spike. Taken together, cell surface binding suggests that while both A19-46.1 and LY-CoV1404 are likely to retain potent neutralizing activity against B.1.1.529, the remaining antibodies in our panel might show decreased neutralizing activity.</p>
<p id="P12">Using the same panel of monoclonal antibodies, we further assayed for each antibody’s capacity to neutralize the B.1.1.529 variant. While VH1-58 supersite antibodies (Class I) show high neutralization activity against other variants, antibodies targeting the supersite were 40 to 126-fold worse (IC<sub>50</sub> 38-269 ng/ml) against B.1.1.529 viruses than D614G (IC<sub>50</sub> 0.9-2.0 ng/ml) (<xref ref-type="fig" rid="F2">Fig 2C</xref>). In addition, two other antibodies, CB6 (Class I) and ADG2 (Class I/IV) were shown to be severely impacted (IC<sub>50</sub> &gt;10,000 ng/mL CB6 and 2037 ng/mL ADG2 to B.1.1.529 vs 31 and 50.5 ng/mL to D614G, respectively) (<xref ref-type="fig" rid="F2">Fig 2C</xref>). We next analyzed Class II antibodies (i.e., LY-CoV555, C144, A19-46.1) and found that amongst these, neutralization by LY-CoV555 and C144 was completely abolished (IC<sub>50</sub> &gt;10,000 ng/mL B.1.1.529 vs 3.6 and 5.1 ng/mL D614G, respectively). In contrast, we found that the A19-46.1 IC<sub>50</sub> neutralization was 223 ng/mL for B.1.1.529 vs 19.4 ng/mL for D614G (<xref ref-type="fig" rid="F2">Fig 2C</xref>) and was &lt;6 fold of the previously reported IC<sub>50</sub> for WA-1 (39.8 ng/mL) (<xref ref-type="bibr" rid="R14">14</xref>). We next analyzed the Class III antibodies (<italic>i.e.,</italic> A19-61.1, REGN10987, COV2-2130, C135, LY-CoV1404) and noted neutralization activity of A19-61.1, REGN10987 and C135 was completely abolished (IC<sub>50</sub> &gt;10,000 ng/mL B.1.1.529 vs 19.4, 20.0, 10.8 ng/mL, respectively on D614G), CoV2-2130 decreased 1581-fold (IC<sub>50</sub> 5850 ng/mL B.1.1.529 vs 3.7 ng/mL D614G) and that of S309 decreased by ~8-fold (IC<sub>50</sub> 281 ng/mL B.1.1.529 vs 36.1 ng/mL D614G) (<xref ref-type="fig" rid="F2">Fig 2C</xref>). Strikingly, in contrast to all of the other antibodies, we found that the neutralization of LY-CoV1404 against B.1.1.529 was unchanged relative to D614G (IC<sub>50</sub> 5.1 ng/mL for B.1.1.529 vs 3 ng/mL for D614G) (<xref ref-type="fig" rid="F2">Fig 2C</xref>). Taken together, these data demonstrate that the mutations present in B.1.1.529 mediate resistance to antibodies.</p>
</sec>
<sec id="S5">
<title>Structural and functional basis of Class I antibody neutralization, escape and retained potency</title>
<p id="P13">We sought to determine the functional basis of B.1.1.529 neutralization and escape for Class I antibodies and to understand how potent neutralization might be retained. We analyzed Class I antibodies, CB6, B1-182.1 and S2E12, with differential B.1.1.529 neutralization (<xref ref-type="fig" rid="F2">Fig 2C</xref>). We first evaluated CB6 using virus particles containing single amino acid substitutions representing 13 of 15 single amino acid changes on the RBD of B.1.1.529 (<italic>i.e</italic>., all but S375F and G496S) or G496R; we noted while several minimally changed their neutralization IC<sub>50</sub>, only Y505H, S371L, Q493R and K417N decreased neutralization &gt;5-fold, with IC<sub>50</sub> of 50, 212, 320, and &gt;10,000 ng/mL, respectively (<xref ref-type="fig" rid="F3">Fig 3A</xref>). This suggests that B.1.1.529 evades CB6-like antibodies through multiple mutations. Docking of the RBD-bound CB6 onto the B.1.1.529 structure revealed several B.1.1.529 residues may potentially clash with CB6. Especially, K417N, Q493R and Y505H were positioned to cause severe steric hindrance to the CB6 paratope, consistent with the neutralization data (<xref ref-type="fig" rid="F3">Fig. 3B</xref>). We next evaluated two VH1-58 supersite antibodies, B1-182.1 and S2E12, which have highly similar amino acid sequences but show ~6-fold difference in B.1.1.529 neutralizing. These two antibodies remained highly potent (&lt;10.6 ng/mL IC<sub>50</sub>) for all virus particles with single RBD mutations, with the largest change for Q493R, which caused a 7 and 5.4-fold decrease of neutralization for B1-182.1 and S2E12, respectively. These small differences in neutralization from single mutations suggest that multiple mutations of B.1.1.529 are working in concert to mediate escape from VH1-58 supersite antibodies. Docking of the RBD-bound B1-182.1 onto the B.1.1.529 structure indicated that the epitopes of these VH1-58-derived antibodies were confined by Q493R, S477N, T478K and E484A (<xref ref-type="fig" rid="F3">Fig. 3C</xref>). With R493 pressing on one side of the antibody like a thumb, N477/K478 squeezed onto the other side of the antibody at the heavy-light chain interface like index and middle fingers (<xref ref-type="fig" rid="F3">Fig. 3C</xref>). Analysis of the docked RBD-antibody complex showed that N477/K478 positioned at the junction formed by CDR H3, CDR L1 and L2 with slight clashes to a region centered at CDR H3 residue 100C (Kabat numbering) (<xref ref-type="fig" rid="F3">Fig. 3D</xref>). Sequence alignment of CDR H3 of VH1-58-derived antibodies indicated that residue 100C varied in sidechain sizes, from serine in S2E12 to tyrosine in A23-58.1. Analysis showed that size of 100C reversely correlated with neutralization potency IC<sub>80</sub> (<italic>p</italic>=0.046) (<xref ref-type="fig" rid="F3">Fig. 3D</xref>, <xref ref-type="fig" rid="F2">Fig. 2C</xref>), suggesting VH1-58 antibodies could alleviate escape imposed by the B.1.1.529 mutations through reduced side chain size at position 100C to minimize clashes from N477/K478.</p>
</sec>
<sec id="S6">
<title>Structural and functional basis of Class II antibody neutralization, escape and retained potency</title>
<p id="P14">We next sought to determine the functional basis of B.1.1.529 neutralization and escape for two Class II antibodies, LY-CoV555 (<xref ref-type="bibr" rid="R26">26</xref>) and A19-46.1 (<xref ref-type="bibr" rid="R14">14</xref>), which have B.1.1.529 IC<sub>50</sub> of &gt;10,000 and 223 ng/mL, respectively (<xref ref-type="fig" rid="F2">Fig 2C</xref>). By assessing the impact of each of the single amino acid changes in RBD from B.1.1.529, we found that for LY-CoV555, either E484A or Q493R resulted in complete loss of LY-CoV555 neutralization (IC<sub>50</sub> &gt;10,000 ng/mL) (<xref ref-type="fig" rid="F4">Fig 4A</xref>), while the same mutations did not affect A19-46.1. For A19-46.1, no individual mutation reduce neutralization to the level noted in B.1.1.529; S371L had the highest effect, reducing the IC<sub>50</sub> to 72.3 ng/mL relative to 223 ng/mL for B.1.1.529. One potential explanation for this is that the Phe-Phe interaction, between 375 and 486, occurs in the context of three B1.1.529 alterations, S371L/S373P/S375F (<xref ref-type="fig" rid="F1">Fig. 1B</xref>).</p>
<p id="P15">To understand the structural basis of A19-46.1 neutralization of B.1.1.529, we obtained cryo-EM structure of the B.1.1.529 spike in complex with Fab A19-46.1 at 3.86 Å resolution (<xref ref-type="fig" rid="F4">Fig 4B</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S5 and Table S2</xref>). The structure revealed that two Fabs bound to the RBD in the “up” conformation in each spike with the third RBD in down position. Focused local refinement of the antibody-RBD region resolved the antibody-RBD interface (<xref ref-type="fig" rid="F4">Fig. 4B</xref>, right). Consistent with previous mapping and negative stain EM data, A19-46.1 binds to a region on RBD generally targeted by the Class II antibodies with an angle approximately 45 degrees towards the viral membrane. Binding involves all light chain CDRs and only CDR H3 of the heavy chain and buried a total of 805 Å<sup>2</sup> interface area from the antibody (<xref ref-type="fig" rid="F4">Fig. 4C</xref>, left). With the light chain latching to the outer rim of the RBD and providing about 70 % of the binding surface, A19-46.1 uses its 17-residue-long CDR H3 to form parallel strand interactions with RBD residues 345-350 (<xref ref-type="fig" rid="F4">Fig. 4B</xref>, right) like a sway brace. Docking RBD-bound ACE2 to the A19-46.1-RBD complex indicated that the bound antibody sterically clashes with ACE2 (<xref ref-type="fig" rid="F4">Fig. 4D</xref>), providing the structural basis for its neutralization of B.1.1.529.</p>
<p id="P16">The 686 Å<sup>2</sup> epitope of A19-46.1 is located within an RBD region that lacks amino acid changes found in B.1.1.529. Of the 15 amino acid changes on RBD, three of residues, S446, A484 and R493, positioned at the edge of epitope with their side chains contributing 8% of the binding surface. LY-CoV555, which targets the same region as a class II antibody, completely lost activity against B.1.1529. To gain structural insights on the viral escape of LY-CoV555, we superimposed the LY-CoV555-RBD complex onto the B.1.1.529 RBD. Even though LY-CoV555 approached the RBD with similar orientation to that of A19-46.1 (<xref ref-type="fig" rid="F4">Fig. 4D</xref>), its epitope shifted up to the ridge of the RBD and embraced B.1.1.529 alterations A484 and R493 within the boundary (<xref ref-type="fig" rid="F4">Fig. 4D</xref>). Inspection of the superimposed structures indicated B.1.1.529 alteration R493 caused steric clash with the CDR H3 of LY-CoV555, explaining the escape of B.1.1.529 from LY-CoV555 neutralization. Overall, the location of the epitope and the angle of approach allowed A19-46.1 to effectively neutralize B.1.1.529.</p>
</sec>
<sec id="S7">
<title>Structural and functional basis of Class III antibody neutralization, escape and retained potency</title>
<p id="P17">To evaluate the functional basis of B.1.1.529 neutralization and escape for Class III antibodies and to understand how potent neutralization might be retained, we investigated a panel of Class III antibodies with differential potency, including A19-61.1, COV2-2130, S309 and LY-CoV1404 (<xref ref-type="fig" rid="F5">Fig 5A</xref>). Assessment of the impact of each of the 15 mutations in RBD revealed the G446S amino acid change results in a complete loss in activity for A19-61.1; consistent with the complete loss of function of this antibody against B.1.1.529. For S309, we observed S373P and G496R to result in small changes to neutralization. Surprisingly, while S309 retains moderate neutralizing activity against B.1.1.529, we found the S371L amino acid change to abolish S309 neutralization. This suggests that combinations of S371L with other B.1.1.529 mutations can result in structural changes in spike that allows S309 to partially overcome the S371L change. The evaluation of COV2-2130 did not identify significant differences in neutralization, suggesting a role for an untested mutation or combinations of amino acid changes for the decrease in neutralization potency observed against the full virus. Finally, consistent with the overall high potency of LY-CoV1404 against all tested VOCs, we did not identify an amino acid change that impacted its function.</p>
<p id="P18">To understand the structural basis of Class III antibody neutralization and viral escape, we determined the cryo-EM structure of WA-1 S2P in complex with Fab A19-61.1 (and Fab B1-182.1 to aid EM resolution of local refinement) at 2.83 Å resolution (<xref ref-type="fig" rid="F5">Fig. 5B</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S6 and Table S1</xref>). The structure revealed that two RBDs were in the up-conformation with both antibodies bound, and the third RBD was in the down-position with only A19-61.1 bound, indicating A19-61.1 could recognize RBD in both up and down conformation (<xref ref-type="fig" rid="F5">Fig. 5B</xref>). Local refinement of the RBD-Fab A19-61.1 region showed that A19-61.1 targeted the Class III epitope with interactions provided by the 18-residue-long CDR H3 from the heavy chain, and all CDRs from the light chain (<xref ref-type="fig" rid="F5">Fig. 5B</xref>). Docking the A19-61.1 structure to the B.1.1.529 spike structure indicated B.1.1.529 mutations S446, R493 and S496 might interfere with A19-61.1. Analysis of the side chain interaction identified Y111 in CDR H3 posed severe clash with S446 in RBD that could not be resolved by loop flexibility (<xref ref-type="fig" rid="F5">Fig. 5C</xref>), explaining the loss of A19-61.1 neutralization against G446S-containding SARS-CoV-2 variants.</p>
<p id="P19">Neutralization assays indicated that COV2-2130, S309 and LY-CoV1404 retained neutralization potency against B.1.1.529. Docking of CoV2-2130 indicated that CoV2-2130 targeted a very similar epitope to that of A19-61.1 with interactions mainly mediated by its CDR L1 and L2 and avoiding close contact with R493 and S496. However, the OH group at the tip of Y50 in CDR L2 posed a minor clash with S446 in RBD, explaining the structural basis for the partial conservation of neutralization by CoV2-2130 (<xref ref-type="fig" rid="F5">Fig. 5D</xref>). Antibody S309 showed higher potency against B.1.1.529 than CoV2-2130. Docked complex of S309 and RBD showed the G339D mutation is located inside the epitope and clashes with CDR H3 Y100, however, the void space between S309 and RBD might accommodate an alternate tyrosine rotamer. The S371L/S373P/S375F mutations changed the conformation of their residing loop and may push the glycan on N343 towards S309 to reduce binding (<xref ref-type="fig" rid="F5">Fig. 5E</xref>). LY-CoV1404 was not affected by B.1.1.529 mutations. Docking of the LY-CoV1404 onto the B.1.1.529 RBD identified four amino acid substitutions located at the edge of its epitope. Three of the residues, K440, R498 and Y501, only make limited side chain interactions with LY-CoV1404. The 4<sup>th</sup> residue, G446S, appeared to cause a potential clash with CDR H2 R60. However, comparison of both LY-CoV1404-bound and non-bound RBD indicated the loop where S446 resided had conformational flexibility to allow LY-CoV1404 binding (<xref ref-type="fig" rid="F5">Fig. 5F</xref>). Overall, the epitopes to Class III antibodies were mainly located on mutation-free RDB surfaces with edges contacting a few B.1.1.529 alterations (<xref ref-type="fig" rid="F5">Fig. 5G</xref>). LY-CoV1404 retained high potency by accommodating all four B.1.1.529 alteration at edge of its epitope by exploiting loop mobility or by minimizing side chain interactions.</p>
</sec>
<sec id="S8">
<title>Synergistic neutralization by the combination of B1-182-1 and A19-46.1</title>
<p id="P20">We previously reported that the combination of B1-182.1 and either A19-46.1 or A19-61.1 mitigated mutational escape in an <italic>in vitro</italic> virus escape assay (<xref ref-type="bibr" rid="R14">14</xref>); suggesting the possibility of synergistic neutralization. We therefore hypothesized that there are combinations of antibodies which lead to an increase in B1.1.529 neutralization beyond that of the two antibodies alone. As a test of this hypothesis, we determined the neutralization of B.1.1.529 pseudotyped viruses by clinically utilized cocktails or various combinations of B1-182.1, A19-46.1, A19-61.1, LY-CoV1404, ADG2 and S309. Of the 10 combinations evaluated only COV2-2196/COV2-2130, B1-182.1/A19-46.1 and B1-182.1/S309 neutralized B.1.1.529 with an appreciably improved potency (<italic>i.e.,</italic> IC<sub>50</sub> of 50.8, 28.3 and 58.1 ng/mL) over the individual component antibodies (<xref ref-type="fig" rid="F6">Fig 6A, B</xref>). Each of these utilized a VH-158 supersite antibody and showed a 5 to 115-fold improvement over the component antibodies (<xref ref-type="fig" rid="F6">Fig 6B</xref>), suggesting an effect that is more than an additive for the specific combination against B.1.1.529.</p>
<p id="P21">To understand the structural basis of the improved neutralization by the cocktail of B1-182.1 and A19-46.1 we determined the cryo-EM structure of the B.1.1.529 S2P spike in complex with Fabs of B1-182.1 and A19-46.1 at 3.86 Å resolution (<xref ref-type="fig" rid="F6">Fig. 6C</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S7 and Table S1</xref>). The prevalent 3D reconstruction revealed that the spike recognized by the combination of these two antibodies was the 3-RBD-up conformation with both Fabs bound to each RBD (Fabs on one of the RBDs were lower in occupancy). The spike had a 1.6 Å RMSD relative to the 3-RBD-up WA-1 structure (PDB ID: 7KMS). Overall, the structure showed that both Class I and II antibodies were capable of simultaneously recognizing the same RBD, and the combination increased the overall stoichiometry compared to two Fabs per trimer observed in the S2P-A19-46.1 structure described above. Of all the antibodies tested, we note that all VH1-58-derived antibodies retained reasonable level of neutralization against B.1.1.529 while members of other antibody classes suffered complete loss of activity. VH1-58 antibodies have minimal numbers of impacting B.1.1.529 alterations in their epitopes and can evolve means to alleviate the impact. We speculate that binding of the first antibody induced the spike into RBD-up-conformation and facilitated binding of the second RBD-up-conformation preferring antibody, thereby synergistically increasing the neutralization potency of the cocktail compared to the individual antibodies.</p>
</sec>
</sec>
<sec id="S9" sec-type="discussion">
<title>Discussion</title>
<p id="P22">SARS-CoV2 variants of concern provide a window into the co-evolution of key host-pathogen interactions between the viral spike, human ACE2 receptor and the human immune system. The RBD is a major target for neutralizing antibodies in both survivors and vaccinees. Since 15 of the 37 mutations in the B.1.1.529 variant spike reside within the RBD, there is a great need to understand the mechanisms by which RBD variations evolve, what constraints exist on the evolution and whether there are approaches that can be taken to exploit this understanding to develop and maintain effective antibody therapeutics and vaccines.</p>
<p id="P23">The B.1.1.529 cryo-EM structure showed a cluster of RBD mutations proximal to the ACE2-binding surface, which alters the electrostatic potential of the interface. However, in contrast to studies that showed increased human ACE2 affinity to mutated and variant RBD subdomains (<xref ref-type="bibr" rid="R20">20</xref>, <xref ref-type="bibr" rid="R34">34</xref>, <xref ref-type="bibr" rid="R35">35</xref>), our studies found that in the context of trimeric spike proteins, variant amino acid changes did not provide a biologically meaningful alteration in affinity. This suggests that there is either no further fitness benefit to be gained by improving affinity, that affinity improving changes are being used to compensate for mutations that are deleterious for ACE2 binding but allow immune escape, or both.</p>
<p id="P24">We used a series of functional and structural studies to define the mechanisms by which B.1.1.529 is either neutralized by or mediates escape from host immunity. To functionally frame our analyses, we utilized the Barnes classification, which categorizes antibodies based on their binding to the ACE2 binding site and the position of RBD. Our findings for Class I VH1-58 supersite showed that B.1.1.529 requires a series of mutation that are not individually deleterious to bracket the antibody and reduce its potency. Notably our data suggests that VH1-58 antibodies can alleviate the deleterious impact of this pinching effect by reducing the size of CDR H3 residue 100C to avoid clashes from B.1.1.529 mutations. Since VH1-58 supersite are amongst the most potent and broadly neutralizing anti-SARS-CoV-2 antibodies (<xref ref-type="bibr" rid="R14">14</xref>, <xref ref-type="bibr" rid="R25">25</xref>, <xref ref-type="bibr" rid="R29">29</xref>, <xref ref-type="bibr" rid="R36">36</xref>), our findings point the way toward structure-based designs of existing antibodies to mitigate against amino acid changes at these positions.</p>
<p id="P25">For the Class II antibody A19-46.1, the angle of approach and a long-CDRH3 combine allow it to target the mutation-free face on RBD and minimize contacting the mutations on the ridge of B.1.1.529 RBD. We observed that A19-46.1 binding requires the RBD-up conformation, and that the S371L substitution, which is located away from the A19-46.1 epitope and near the RBD hinge, partially reduces the neutralization of A19-46.1. Comparing the effect of S371L on neutralization by A19-46.1 and LY-CoV555 (<xref ref-type="fig" rid="F4">Fig. 4A</xref>), which recognizes both RBD-up and -down conformation, suggested that L371 (and potentially P373/F375) is critical for controlling the RBD-up or -down conformation in B.1.1.529. This concept is supported by the finding that combination with a Class I antibody (such as B1-182.1) synergistically enhances A19-46.1 neutralization (<xref ref-type="fig" rid="F6">Fig. 6A</xref>).</p>
<p id="P26">For Class III antibodies, only one prototype antibody showed complete loss of B.1.1.529 neutralization. Using structural and functional approaches we determined that viral escape was mediated by the G446S amino acid change. This result indicates that potent Class III antibodies might be induced through structure-based vaccine designs that mask residue 446 in RBD. Additionally, the existence of G446S sensitive and resistant antibodies with significant epitope overlap suggest the use of spikes with G446S substitution can be utilized to evaluate the quality of Class III immune response in serum-based epitope mapping assays (<xref ref-type="bibr" rid="R37">37</xref>, <xref ref-type="bibr" rid="R38">38</xref>).</p>
<p id="P27">Our analysis of antibodies of clinical importance is consistent with previous reports (<xref ref-type="bibr" rid="R32">32</xref>, <xref ref-type="bibr" rid="R39">39</xref>–<xref ref-type="bibr" rid="R41">41</xref>) and showed that S309 and COV2-2196 neutralized to similar degrees. Importantly, we report that unlike other antibodies, the highly potent LY-CoV1404 does not lose neutralization potency against B.1.1.529. We identified combinations of antibodies that show more than additive increases in neutralization against B.1.1.529, including COV2-2196/COV2-2130, B1-182.1/A19-46.1 and B1-182.1/S309. Each pair contains a VH1-58 supersite antibody that binds RBD in the up position. We speculated that pairing antibodies that neutralize better in the up-RBD conformation with these VH1-58 antibodies may provide a mechanism for better neutralization by the former. The S371L/S373P/S375F alterations in the RBD-up protomer form interprotomer interactions to RBD in the RBD-down protomer and stabilize the B.1.1.529 spike into a single-RBD-up conformation. RBD-up-preferring antibody like the VH1-58-derived B1-182.1, which is not affected by S371L substitution, can effectively break up the interaction to induce the 3-RBD-up conformation and therefore, enhance binding of other antibodies (such as A19-46.1) that require the RBD up-conformation. The identification of SARS-CoV-2 monoclonal antibodies that cooperatively function is similar to that seen previously for other viruses (<xref ref-type="bibr" rid="R42">42</xref>), and supports the concept of using combinations to both enhance potency and mitigate the risk of escape.</p>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary material</label>
<media xlink:href="EMS141212-supplement-Supplementary_material.pdf" mimetype="application" mime-subtype="pdf" id="N66723" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S10">
<title>Acknowledgments</title>
<p>We thank N.A. Doria-Rose, W.-P. Kong, S. O’Dell and S.D. Schmitt and for assistance in B.1.1.529 plasmid production and distribution, M. Kanekiyo for cell line assistance, J. Stuckey and S. Wang for assistance with manuscript preparation and submission, and members of the Virology Laboratory, Vaccine Research Center, for discussions and comments on the manuscript. We thank S Žentelis, E. Lameignere and K. Westerndorf for antibody LY-CoV1404. We are grateful to T. Edwards and T.L. Fox of NCEF for cryo-EM data collection and for technical assistance with cryo-EM data processing.</p>
<sec id="S11">
<title>Funding</title>
<p>This work was funded by the Intramural Research Program of the Vaccine Research Center, NIAID, NIH. This research was, in part, supported by the National Cancer Institute’s National Cryo-EM Facility at the Frederick National Laboratory for Cancer Research under contract HSSN261200800001E.</p>
</sec>
</ack>
<sec id="S12" sec-type="data-availability">
<title>Data and materials availability</title>
<p id="P28">All data is available in the main text or the supplementary materials. Atomic coordinates and cryo-EM maps of the reported structure have been deposited into the Protein Data Bank and Electron Microscopy Data Bank under the session codes PDB 7TB4 and EMD-25792 for the SARS-CoV-2 B.1.1.529 VOC spike, PDB 7TCA and EMD-25807 for SARS-CoV-2 B.1.1.529 VOC spike in complex with antibody A19-46.1. PDB 7TC9 and EMD-25806 for local refinement of the SARS-CoV-2 B.1.1.529 VOC RBD in complex with antibody A19-46.1, PDB 7TCC and EMD-25808 for SARS-CoV-2 B.1.1.529 VOC spike in complex with antibodies B1-182.1 and A19-46.1. PDB 7TB8 and EMD-25794 for SARS-CoV-2 WA-1 spike in complex with antibodies A19-61.1 and B1-182.1, PDB 7TBF and EMD-25797 for local refinement of the SARS-CoV-2 WA-1 RBD in complex with antibodies A19-61.1 and antibody B1-182.1. Original materials in this manuscript are available under a materials transfer agreement with the National Institutes of Health.</p>
</sec>
<fn-group>
<fn id="FN3" fn-type="con">
<p id="P29">
<bold>Author contributions</bold>
</p>
<p id="P30">T.Z., L.W., J.M. and A.P. designed experiments and analyzed data. L.W., A.P., Y.Z., D.R.H., C.A.T., A.S.O., E.S.Y., M.C. (Man Chen), K.L. and E.S.D.S. performed experiments. L.W., J.M., A.S.O., W.S., M.C. (Misook Choe), I-T.T., A.C., T.L., B.Z. produced proteins, antibodies and other reagents. T.Z. led electron microscopy studies assisted by C.J., T.S. and Y.T.. J.M., B.S.G., J.R.M., N.J.S. and P.D.K. supervised experiments. T.Z., L.W., J.M., N.J.S., and P.D.K wrote the manuscript with help from all authors.</p>
</fn>
<fn id="FN4" fn-type="conflict">
<p id="P31">
<bold>Competing interests</bold>
</p>
<p id="P32">T.Z., L.W., J.M., A.P., Y.Z., E.S.Y., W.S., J.R.M, N.J.S., and P.D.K. are inventors on US patent application No. 63/147,419. J.R.M, B.S.G., L.W., Y.Z., and W.S. are inventors on PCT/US2020/063991 and PCT/US2021/020843.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<label>1</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>YM</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>ZG</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Tao</surname>
<given-names>ZW</given-names>
</name>
<name>
<surname>Tian</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Pei</surname>
<given-names>YY</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>ML</given-names>
</name>
<etal/>
</person-group>
<article-title>A new coronavirus associated with human respiratory disease in China</article-title>
<source>Nature</source>
<year>2020</year>
<volume>579</volume>
<fpage>265</fpage>
<lpage>269</lpage>
</element-citation>
</ref>
<ref id="R2">
<label>2</label>
<element-citation publication-type="web">
<collab>C. for S. S. and E. at J. H. University</collab>
<source>Johns Hopkins University COVID-19 Dashboard</source>
<year>2021</year>
<comment>available at <ext-link ext-link-type="uri" xlink:href="https://coronavirus.jhu.edu/map.html">https://coronavirus.jhu.edu/map.html</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R3">
<label>3</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cele</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jackson</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Khoury</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Moyo-Gwete</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Scheepers</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Amoako</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Karim</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bernstein</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lustig</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited neutralization and requires ACE2 for infection</article-title>
<source>Mahomed-Yunus S Moosa</source>
<year>2021</year>
<volume>10</volume>
<fpage>11</fpage>
</element-citation>
</ref>
<ref id="R4">
<label>4</label>
<element-citation publication-type="journal">
<collab>O World Health</collab>
<source>Enhancing Readiness for Omicron (B11529): Technical Brief and Priority Actions for Member States</source>
<year>2021</year>
<volume>2021</volume>
<fpage>1</fpage>
<lpage>8</lpage>
</element-citation>
</ref>
<ref id="R5">
<label>5</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sauer</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Czudnochowski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Low</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Alejandra Tortorici</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Housley</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Noack</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Guarino</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>LE</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad betacoronavirus neutralization by a stem helix−specific human antibody</article-title>
<source>Science (80-)</source>
<year>2021</year>
<volume>373</volume>
<fpage>1109</fpage>
<lpage>1116</lpage>
</element-citation>
</ref>
<ref id="R6">
<label>6</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Goldsmith</surname>
<given-names>JA</given-names>
</name>
<name>
<surname>Hsieh</surname>
<given-names>C-L</given-names>
</name>
<name>
<surname>Abiona</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>McLellan</surname>
<given-names>JS</given-names>
</name>
</person-group>
<article-title>Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation</article-title>
<source>Science</source>
<year>2020</year>
<volume>367</volume>
<fpage>1260</fpage>
<lpage>1263</lpage>
</element-citation>
</ref>
<ref id="R7">
<label>7</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yurkovetskiy</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Pascal</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Tomkins-Tinch</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nyalile</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Diehl</surname>
<given-names>WE</given-names>
</name>
<name>
<surname>Dauphin</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Carbone</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Veinotte</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>739</fpage>
<lpage>751</lpage>
<elocation-id>e8</elocation-id>
</element-citation>
</ref>
<ref id="R8">
<label>8</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerutti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gorman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Rapp</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Reddem</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Bahna</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bimela</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite</article-title>
<source>Cell Host Microbe</source>
<year>2021</year>
<volume>29</volume>
<fpage>1</fpage>
<lpage>15</lpage>
</element-citation>
</ref>
<ref id="R9">
<label>9</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rosa</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pye</surname>
<given-names>VE</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muir</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Seow</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ng</surname>
<given-names>KW</given-names>
</name>
<name>
<surname>Cook</surname>
<given-names>NJ</given-names>
</name>
<name>
<surname>Rees-Spear</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Parker</surname>
<given-names>E</given-names>
</name>
<name>
<surname>dos Santos</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Rosadas</surname>
<given-names>C</given-names>
</name>
<etal/>
</person-group>
<article-title>Cherepanov, SARS-CoV-2 can recruit a heme metabolite to evade antibody immunity</article-title>
<source>Sci Adv</source>
<year>2021</year>
<volume>7</volume>
<fpage>1</fpage>
<lpage>15</lpage>
</element-citation>
</ref>
<ref id="R10">
<label>10</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cerutti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Nair</surname>
<given-names>MS</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Katsamba</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Bahna</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Reddem</surname>
<given-names>ER</given-names>
</name>
<etal/>
</person-group>
<article-title>Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain</article-title>
<source>Cell Rep</source>
<year>2021</year>
<volume>37</volume>
<elocation-id>109928</elocation-id>
</element-citation>
</ref>
<ref id="R11">
<label>11</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lan</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Fan</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
</person-group>
<article-title>Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor</article-title>
<source>Nature</source>
<year>2020</year>
<volume>581</volume>
<fpage>215</fpage>
<lpage>220</lpage>
</element-citation>
</ref>
<ref id="R12">
<label>12</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Jette</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Abernathy</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Dam</surname>
<given-names>K-MA</given-names>
</name>
<name>
<surname>Esswein</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Gristick</surname>
<given-names>HB</given-names>
</name>
<name>
<surname>Malyutin</surname>
<given-names>AG</given-names>
</name>
<name>
<surname>Sharaf</surname>
<given-names>NG</given-names>
</name>
<name>
<surname>Huey-Tubman</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>YE</given-names>
</name>
<name>
<surname>Robbiani</surname>
<given-names>DF</given-names>
</name>
<etal/>
</person-group>
<article-title>SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies</article-title>
<source>Nature</source>
<year>2020</year>
<volume>588</volume>
<fpage>682</fpage>
<lpage>687</lpage>
</element-citation>
</ref>
<ref id="R13">
<label>13</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Robbiani</surname>
<given-names>DF</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Muecksch</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Lorenzi</surname>
<given-names>JCC</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Agudelo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Gazumyan</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hägglöf</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>Convergent antibody responses to SARS-CoV-2 in convalescent individuals</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>437</fpage>
<lpage>442</lpage>
</element-citation>
</ref>
<ref id="R14">
<label>14</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>ES</given-names>
</name>
<name>
<surname>Schramm</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Pegu</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Oloniniyi</surname>
<given-names>OK</given-names>
</name>
<name>
<surname>Henry</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Darko</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Narpala</surname>
<given-names>SR</given-names>
</name>
<etal/>
</person-group>
<article-title>Ultrapotent antibodies against diverse and highly transmissible SARS-CoV-2 variants</article-title>
<source>Science (80-)</source>
<year>2021</year>
<volume>373</volume>
<fpage>0</fpage>
<lpage>15</lpage>
</element-citation>
</ref>
<ref id="R15">
<label>15</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rambaut</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Loman</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Pybus</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Barclay</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Barrett</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Carabelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Connor</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Peacock</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Robertson</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Volz</surname>
<given-names>E</given-names>
</name>
<collab>C.-19 G. C. UK</collab>
</person-group>
<article-title>Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations</article-title>
<source>virological.org</source>
<year>2020</year>
<comment>available at <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563">https://virological.org/t/preliminary-genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-the-uk-defined-by-a-novel-set-of-spike-mutations/563</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R16">
<label>16</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wilkinson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Giovanetti</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Iranzadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Fonseca</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giandhari</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Doolabh</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pillay</surname>
<given-names>S</given-names>
</name>
<name>
<surname>San</surname>
<given-names>EJ</given-names>
</name>
<name>
<surname>Msomi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Mlisana</surname>
<given-names>K</given-names>
</name>
<etal/>
</person-group>
<article-title>Detection of a SARS-CoV-2 variant of concern in South Africa</article-title>
<source>Nature</source>
<year>2021</year>
<volume>592</volume>
<fpage>438</fpage>
<lpage>443</lpage>
</element-citation>
</ref>
<ref id="R17">
<label>17</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Faria</surname>
<given-names>NR</given-names>
</name>
<name>
<surname>Claro</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>Candido</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Franco</surname>
<given-names>LAM</given-names>
</name>
<name>
<surname>Andrade</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Coletti</surname>
<given-names>TM</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>CAM</given-names>
</name>
<name>
<surname>Sales</surname>
<given-names>FC</given-names>
</name>
<name>
<surname>Manuli</surname>
<given-names>ER</given-names>
</name>
<name>
<surname>Aguiar</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Gaburo</surname>
<given-names>N</given-names>
</name>
<etal/>
</person-group>
<article-title>Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings</article-title>
<source>virological.org</source>
<year>2021</year>
<comment>available at <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586">https://virological.org/t/genomic-characterisation-of-an-emergent-sars-cov-2-lineage-in-manaus-preliminary-findings/586</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R18">
<label>18</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naveca</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Souza</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Corado</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nascimento</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Silva</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>Á</given-names>
</name>
<name>
<surname>Duarte</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pessoa</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Gonçalves</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Brandão</surname>
<given-names>MJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Phylogenetic relationship of SARS-CoV-2 sequences from Amazonas with emerging Brazilian variants harboring mutations E484K and N501Y in the Spike protein - SARS-CoV-2 coronavirus / nCoV-2019 Genomic Epidemiology - Virological</article-title>
<source>virological.org</source>
<year>2021</year>
<comment>available at <ext-link ext-link-type="uri" xlink:href="https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585">https://virological.org/t/phylogenetic-relationship-of-sars-cov-2-sequences-from-amazonas-with-emerging-brazilian-variants-harboring-mutations-e484k-and-n501y-in-the-spike-protein/585</ext-link>
</comment>
</element-citation>
</ref>
<ref id="R19">
<label>19</label>
<element-citation publication-type="book">
<collab>WHO</collab>
<source>COVID-19 weekly epidemiological update</source>
<publisher-name>World Heal Organ</publisher-name>
<year>2021</year>
<fpage>1</fpage>
<lpage>23</lpage>
</element-citation>
</ref>
<ref id="R20">
<label>20</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Starr</surname>
<given-names>TNN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJJ</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>SKK</given-names>
</name>
<name>
<surname>King</surname>
<given-names>NPP</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bloom</surname>
<given-names>JDD</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TNN</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJJ</given-names>
</name>
<name>
<surname>Hilton</surname>
<given-names>SKK</given-names>
</name>
<name>
<surname>Ellis</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Crawford</surname>
<given-names>KHDHDD</given-names>
</name>
<etal/>
</person-group>
<article-title>Deep Mutational Scanning of SARS-CoV-2 Receptor Binding Domain Reveals Constraints on Folding and ACE2 Binding</article-title>
<source>Cell</source>
<year>2020</year>
<volume>182</volume>
<fpage>1295</fpage>
<lpage>1310</lpage>
<elocation-id>e20</elocation-id>
</element-citation>
</ref>
<ref id="R21">
<label>21</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ryu</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Noh</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Nuijten</surname>
<given-names>PM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>E</given-names>
</name>
<etal/>
</person-group>
<article-title>The in vitro and in vivo efficacy of CT-P59 against Gamma, Delta and its associated variants of SARS-CoV-2</article-title>
<source>Biochem Biophys Res Commun</source>
<year>2021</year>
<volume>578</volume>
<fpage>91</fpage>
<lpage>96</lpage>
</element-citation>
</ref>
<ref id="R22">
<label>22</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Ryu</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Il Kim</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Seo</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>YG</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>JH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>JI</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Bae</surname>
<given-names>JS</given-names>
</name>
<etal/>
</person-group>
<article-title>A therapeutic neutralizing antibody targeting receptor binding domain of SARS-CoV-2 spike protein</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<fpage>1</fpage>
<lpage>10</lpage>
</element-citation>
</ref>
<ref id="R23">
<label>23</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rappazzo</surname>
<given-names>CG</given-names>
</name>
<name>
<surname>Tse</surname>
<given-names>LV</given-names>
</name>
<name>
<surname>Kaku</surname>
<given-names>CI</given-names>
</name>
<name>
<surname>Wrapp</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Sakharkar</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Deveau</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Yockachonis</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Herbert</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Battles</surname>
<given-names>MB</given-names>
</name>
<name>
<surname>O’Brien</surname>
<given-names>CM</given-names>
</name>
<etal/>
</person-group>
<article-title>Broad and potent activity against SARS-like viruses by an engineered human monoclonal antibody</article-title>
<source>Science</source>
<year>2021</year>
<volume>371</volume>
<fpage>823</fpage>
<lpage>829</lpage>
</element-citation>
</ref>
<ref id="R24">
<label>24</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Westendorf</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Žentelis</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Vaillancourt</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Wiggin</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lovett</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Hendle</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pustilnik</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sauder</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Kraft</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hwang</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>LY-CoV1404 potently neutralizes SARS-CoV-2 variants</article-title>
<year>2021</year>
</element-citation>
</ref>
<ref id="R25">
<label>25</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lempp</surname>
<given-names>FA</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Dang</surname>
<given-names>HV</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>McCallum</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Minola</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Jaconi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<article-title>Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>950</fpage>
<lpage>957</lpage>
</element-citation>
</ref>
<ref id="R26">
<label>26</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jones</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Brown-Augsburger</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Westendorf</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Davies</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cujec</surname>
<given-names>TP</given-names>
</name>
<name>
<surname>Wiethoff</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>Blackbourne</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Heinz</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Foster</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Higgs</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group>
<article-title>The neutralizing antibody, LY-CoV555, protects against SARS-CoV-2 infection in non-human primates</article-title>
<source>Sci Transl Med</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1126/scitranslmed.abf1906</pub-id>
</element-citation>
</ref>
<ref id="R27">
<label>27</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Shan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duan</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bi</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Han</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>G</given-names>
</name>
<etal/>
</person-group>
<article-title>A human neutralizing antibody targets the receptor-binding site of SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>120</fpage>
<lpage>124</lpage>
</element-citation>
</ref>
<ref id="R28">
<label>28</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Hansen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Baum</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Pascal</surname>
<given-names>KE</given-names>
</name>
<name>
<surname>Russo</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Giordano</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wloga</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Fulton</surname>
<given-names>BO</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Koon</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Patel</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chung</surname>
<given-names>KM</given-names>
</name>
<etal/>
</person-group>
<article-title>Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail</article-title>
<source>Science</source>
<year>2020</year>
<volume>369</volume>
<fpage>1010</fpage>
<lpage>1014</lpage>
</element-citation>
</ref>
<ref id="R29">
<label>29</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Binshtein</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Nkolola</surname>
<given-names>JP</given-names>
</name>
<name>
<surname>Schäfer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reidy</surname>
<given-names>JX</given-names>
</name>
<name>
<surname>Trivette</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nargi</surname>
<given-names>RS</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>RE</given-names>
</name>
<etal/>
</person-group>
<article-title>Potently neutralizing and protective human antibodies against SARS-CoV-2</article-title>
<source>Nature</source>
<year>2020</year>
<volume>584</volume>
<fpage>443</fpage>
<lpage>449</lpage>
</element-citation>
</ref>
<ref id="R30">
<label>30</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Bianchi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jaconi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Culap</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Peter</surname>
<given-names>A</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-neutralization of SARS-CoV-2 by a human monoclonal SARS-CoV antibody</article-title>
<source>Nature</source>
<year>2020</year>
<volume>583</volume>
<fpage>290</fpage>
<lpage>295</lpage>
</element-citation>
</ref>
<ref id="R31">
<label>31</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Piccoli</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>YJ</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Czudnochowski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Beltramello</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Silacci-Fregni</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Acton</surname>
<given-names>OJ</given-names>
</name>
<etal/>
</person-group>
<article-title>Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology</article-title>
<source>Cell</source>
<year>2020</year>
<volume>183</volume>
<fpage>1024</fpage>
<lpage>1042</lpage>
<elocation-id>e21</elocation-id>
</element-citation>
</ref>
<ref id="R32">
<label>32</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dejnirattisai</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Huo</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Zahradník</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Supasa</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Duyvesteyn</surname>
<given-names>HME</given-names>
</name>
<name>
<surname>Ginn</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Mentzer</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Tuekprakhon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nutalai</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<source>bioRxiv</source>
<comment>in press</comment>
<pub-id pub-id-type="doi">10.1101/2021.12.03.471045</pub-id>
</element-citation>
</ref>
<ref id="R33">
<label>33</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Barnes</surname>
<given-names>CO</given-names>
</name>
<name>
<surname>Weisblum</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Schmidt</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Caskey</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gaebler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cho</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Agudelo</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Finkin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>Mapping mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies</article-title>
<source>Nat Commun</source>
<year>2021</year>
<volume>12</volume>
<pub-id pub-id-type="doi">10.1038/s41467-021-24435-8</pub-id>
</element-citation>
</ref>
<ref id="R34">
<label>34</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tortorici</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Czudnochowski</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Marzi</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Jaconi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>di iulio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zepeda</surname>
<given-names>SK</given-names>
</name>
<etal/>
</person-group>
<source>bioRxiv</source>
<comment>in press</comment>
<pub-id pub-id-type="doi">10.1101/2021.04.07.438818</pub-id>
</element-citation>
</ref>
<ref id="R35">
<label>35</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Woo</surname>
<given-names>HG</given-names>
</name>
</person-group>
<article-title>Omicron : A heavily mutated SARS-CoV-2 variant exhibits stronger binding to ACE2 and potently escape approved COVID-19 therapeutic antibodies</article-title>
<source>bioRxiv</source>
<year>2021</year>
</element-citation>
</ref>
<ref id="R36">
<label>36</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dong</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Greaney</surname>
<given-names>AJ</given-names>
</name>
<name>
<surname>Starr</surname>
<given-names>TN</given-names>
</name>
<name>
<surname>Dingens</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Case</surname>
<given-names>JB</given-names>
</name>
<name>
<surname>Sutton</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Gilchuk</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Rodriguez</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Genetic and structural basis for recognition of SARS-CoV-2 spike protein by a two-antibody cocktail</article-title>
<source>bioRxiv Prepr Serv Biol</source>
<year>2021</year>
<pub-id pub-id-type="doi">10.1101/2021.01.27.428529</pub-id>
</element-citation>
</ref>
<ref id="R37">
<label>37</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ko</surname>
<given-names>SH</given-names>
</name>
<name>
<surname>Bayat Mokhtari</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Mudvari</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Stein</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Stringham</surname>
<given-names>CD</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ramelli</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ramos-Benitez</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Strich</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Davey</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>T</given-names>
</name>
<etal/>
</person-group>
<article-title>High-throughput, single-copy sequencing reveals SARS-CoV-2 spike variants coincident with mounting humoral immunity during acute COVID-19</article-title>
<source>PLOS Pathog</source>
<year>2021</year>
<volume>17</volume>
<elocation-id>e1009431</elocation-id>
</element-citation>
</ref>
<ref id="R38">
<label>38</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Corbett</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Gagne</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wagner</surname>
<given-names>DA</given-names>
</name>
<name>
<surname>O’Connell</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Narpala</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Flebbe</surname>
<given-names>DR</given-names>
</name>
<name>
<surname>Andrew</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Davis</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Flynn</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Johnston</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Stringham</surname>
<given-names>CD</given-names>
</name>
<etal/>
</person-group>
<article-title>Protection against SARS-CoV-2 Beta variant in mRNA-1273 vaccine-boosted nonhuman primates</article-title>
<source>Science (80-)</source>
<year>2021</year>
<volume>374</volume>
<fpage>1343</fpage>
<lpage>1353</lpage>
</element-citation>
</ref>
<ref id="R39">
<label>39</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cameroni</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Saliba</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bowen</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Rosen</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Culap</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Pinto</surname>
<given-names>D</given-names>
</name>
<name>
<surname>VanBlargan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>De Marco</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zepeda</surname>
<given-names>SK</given-names>
</name>
<name>
<surname>di Iulio</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zatta</surname>
<given-names>F</given-names>
</name>
<etal/>
</person-group>
<source>bioRxiv</source>
<comment>in press</comment>
<pub-id pub-id-type="doi">10.1101/2021.12.12.472269</pub-id>
</element-citation>
</ref>
<ref id="R40">
<label>40</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cao</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jian</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Xiao</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Yisimayi</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>P</given-names>
</name>
<name>
<surname>An</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<source>bioRxiv</source>
<comment>in press</comment>
<pub-id pub-id-type="doi">10.1101/2021.12.07.470392</pub-id>
</element-citation>
</ref>
<ref id="R41">
<label>41</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>VanBlargan</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Errico</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Halfmann</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Zost</surname>
<given-names>SJ</given-names>
</name>
<name>
<surname>Crowe</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Purcell</surname>
<given-names>LA</given-names>
</name>
<name>
<surname>Kawaoka</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Corti</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Fremont</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Diamond</surname>
<given-names>MS</given-names>
</name>
</person-group>
<source>bioRxiv</source>
<comment>in press</comment>
<pub-id pub-id-type="doi">10.1101/2021.12.15.472828</pub-id>
</element-citation>
</ref>
<ref id="R42">
<label>42</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Howell</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Brannan</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Bryan</surname>
<given-names>C</given-names>
</name>
<name>
<surname>McNeal</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Davidson</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>HL</given-names>
</name>
<name>
<surname>Vu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Shulenin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>He</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kuehne</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Herbert</surname>
<given-names>AS</given-names>
</name>
<etal/>
</person-group>
<article-title>Cooperativity Enables Non-neutralizing Antibodies to Neutralize Ebolavirus</article-title>
<source>Cell Rep</source>
<year>2017</year>
<volume>19</volume>
<fpage>413</fpage>
<lpage>424</lpage>
</element-citation>
</ref>
<ref id="R43">
<label>43</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Teng</surname>
<given-names>I-T</given-names>
</name>
<name>
<surname>Olia</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Cerutti</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Gorman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Nazzari</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Tsybovsky</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>B</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure-Based Design with Tag-Based Purification and In-Process Biotinylation Enable Streamlined Development of SARS-CoV-2 Spike Molecular Probes</article-title>
<source>Cell Rep</source>
<year>2020</year>
<volume>33</volume>
<elocation-id>108322</elocation-id>
</element-citation>
</ref>
<ref id="R44">
<label>44</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McLellan</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Pancera</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Carrico</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gorman</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Julien</surname>
<given-names>J-P</given-names>
</name>
<name>
<surname>Khayat</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Louder</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pejchal</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Sastry</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>K</given-names>
</name>
<name>
<surname>O’Dell</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Structure of HIV-1 gp120 V1/V2 domain with broadly neutralizing antibody PG9</article-title>
<source>Nature</source>
<year>2011</year>
<volume>480</volume>
<fpage>336</fpage>
<lpage>43</lpage>
</element-citation>
</ref>
<ref id="R45">
<label>45</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moyo-Gwete</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Madzivhandila</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Makhado</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Ayres</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Mhlanga</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Oosthuysen</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Lambson</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Kgagudi</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Tegally</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Iranzadeh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Doolabh</surname>
<given-names>D</given-names>
</name>
<etal/>
</person-group>
<article-title>Cross-Reactive Neutralizing Antibody Responses Elicited by SARS-CoV-2 501Y.V2 (B.1.351)</article-title>
<source>N Engl J Med</source>
<year>2021</year>
<volume>2</volume>
<pub-id pub-id-type="doi">10.1056/NEJMc2104192</pub-id>
</element-citation>
</ref>
<ref id="R46">
<label>46</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Barouch</surname>
<given-names>DH</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Korioth-Schmitz</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Sumida</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Truitt</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Kishko</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Arthur</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Miura</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Mascola</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Letvin</surname>
<given-names>NL</given-names>
</name>
<etal/>
</person-group>
<article-title>A Human T-Cell Leukemia Virus Type 1 Regulatory Element Enhances the Immunogenicity of Human Immunodeficiency Virus Type 1 DNA Vaccines in Mice and Nonhuman Primates</article-title>
<source>J Virol</source>
<year>2005</year>
<volume>79</volume>
<fpage>8828</fpage>
<lpage>8834</lpage>
</element-citation>
</ref>
<ref id="R47">
<label>47</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Catanzaro</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Roederer</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Koup</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Bailer</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Enama</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Nason</surname>
<given-names>MC</given-names>
</name>
<name>
<surname>Martin</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Rucker</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>CA</given-names>
</name>
<name>
<surname>Gomez</surname>
<given-names>PL</given-names>
</name>
<name>
<surname>Mascola</surname>
<given-names>JR</given-names>
</name>
<etal/>
</person-group>
<article-title>VRC 007 Study Team, Phase I clinical evaluation of a six-plasmid multiclade HIV-1 DNA candidate vaccine</article-title>
<source>Vaccine</source>
<year>2007</year>
<volume>25</volume>
<fpage>4085</fpage>
<lpage>92</lpage>
</element-citation>
</ref>
<ref id="R48">
<label>48</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naldini</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Blomer</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Gage</surname>
<given-names>FH</given-names>
</name>
<name>
<surname>Trono</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Verma</surname>
<given-names>IM</given-names>
</name>
</person-group>
<article-title>Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>1996</year>
<volume>93</volume>
<fpage>11382</fpage>
<lpage>11388</lpage>
</element-citation>
</ref>
<ref id="R49">
<label>49</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Yang</surname>
<given-names>ZY</given-names>
</name>
<name>
<surname>Werner</surname>
<given-names>HC</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>WP</given-names>
</name>
<name>
<surname>Leung</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Traggiai</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Lanzavecchia</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Nabel</surname>
<given-names>GJ</given-names>
</name>
</person-group>
<article-title>Evasion of antibody neutralization in emerging severe acute respiratory syndrome coronaviruses</article-title>
<source>Proc Natl Acad Sci U S A</source>
<year>2005</year>
<volume>102</volume>
<fpage>797</fpage>
<lpage>801</lpage>
</element-citation>
</ref>
<ref id="R50">
<label>50</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Punjani</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rubinstein</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Fleet</surname>
<given-names>DJ</given-names>
</name>
<name>
<surname>Brubaker</surname>
<given-names>MA</given-names>
</name>
</person-group>
<article-title>CryoSPARC: Algorithms for rapid unsupervised cryo-EM structure determination</article-title>
<source>Nat Methods</source>
<year>2017</year>
<volume>14</volume>
<fpage>290</fpage>
<lpage>296</lpage>
</element-citation>
</ref>
<ref id="R51">
<label>51</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Afonine</surname>
<given-names>PV</given-names>
</name>
<name>
<surname>Grosse-Kunstleve</surname>
<given-names>RW</given-names>
</name>
<name>
<surname>Echols</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Headd</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Moriarty</surname>
<given-names>NW</given-names>
</name>
<name>
<surname>Mustyakimov</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Terwilliger</surname>
<given-names>TC</given-names>
</name>
<name>
<surname>Urzhumtsev</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Zwart</surname>
<given-names>PH</given-names>
</name>
<name>
<surname>Adams</surname>
<given-names>PD</given-names>
</name>
</person-group>
<article-title>Towards automated crystallographic structure refinement with phenix</article-title>
<source>refine Acta Crystallogr Sect D Biol Crystallogr</source>
<year>2012</year>
<volume>68</volume>
<fpage>352</fpage>
<lpage>367</lpage>
</element-citation>
</ref>
<ref id="R52">
<label>52</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Davis</surname>
<given-names>IW</given-names>
</name>
<name>
<surname>Murray</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Richardson</surname>
<given-names>DC</given-names>
</name>
</person-group>
<article-title>MolProbity: Structure validation and all-atom contact analysis for nucleic acids and their complexes</article-title>
<source>Nucleic Acids Res</source>
<year>2004</year>
<volume>32</volume>
<fpage>615</fpage>
<lpage>619</lpage>
</element-citation>
</ref>
<ref id="R53">
<label>53</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Pettersen</surname>
<given-names>EF</given-names>
</name>
<name>
<surname>Goddard</surname>
<given-names>TD</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>CC</given-names>
</name>
<name>
<surname>Couch</surname>
<given-names>GS</given-names>
</name>
<name>
<surname>Greenblatt</surname>
<given-names>DM</given-names>
</name>
<name>
<surname>Meng</surname>
<given-names>EC</given-names>
</name>
<name>
<surname>Ferrin</surname>
<given-names>TE</given-names>
</name>
</person-group>
<article-title>UCSF Chimera - A visualization system for exploratory research and analysis</article-title>
<source>J Comput Chem</source>
<year>2004</year>
<volume>25</volume>
<fpage>1605</fpage>
<lpage>1612</lpage>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<boxed-text id="BX1" position="float" orientation="portrait">
<caption>
<title>Summary Sentence</title>
</caption>
<p>We show potent B.1.1.529 neutralization by select antibodies and use EM structures to reveal how potency can be retained.</p>
</boxed-text>
<fig id="F1" position="float">
<label>Figure 1</label>
<caption>
<title>Cryo-EM structure of the SARS-CoV-2 B.1.1.529 (Omicron) spike.</title>
<p>A. Cryo-EM map of the SARS-CoV-2 B.1.1.529 spike. Reconstruction density map at 3.29 Å resolution is shown with side and top views. Protomers are colored light green, wheat and light blue. The contour level of cryo-EM map is 4.0s.</p>
<p>B. B.1.1.529 amino acid substitutions introduced inter-protomer interactions. Substitutions in one protomer are shown as red spheres. Examples of inter-protomer interactions introduced by B.1.1.529 substitutions were highlighted in box with zoom-in view to the side. Mutation are described as a percentage of the domain surface (surface) or as a percentage of the sequence (seq).</p>
<p>C. The NTD supersite of vulnerability is shown in semi-transparent surface along with a green backbone ribbon. Amino acid substitutions, deletions, and insertions are colored red.</p>
<p>D. The 15 amino acid substitutions clustered on the rim of RBD, changed 16 % of the RBD surface areas (left) and increased electro-positivity of the ACE2-binding site (right). Mutated residues were shown in red sticks. The ACE2-binding site on the electrostatic potential surface were marked as magenta lines.</p>
<p>E. Mapping B.1.1.529 RBD substitutions on the epitopes of Barnes Class I-IV antibodies. The locations of the substitutions were shown in red on the surface. Those may potentially affect the activity of antibodies in each class were labeled with their residue numbers. Class I footprint were defined by epitopes of CB6 and B1-182.1, Class II footprint were defined by epitopes of A19-46.1 and LY-CoV555, Class III footprint were defined by epitopes of A19-61.1, COV2-2130, LY-CoV1404 and S309, Class IV footprint were defined by epitopes of DH1407 and S304. Class I and II epitope have overlap with the ACE2 binding site, while class III and IV do not. Class II and III epitopes allow binding to WA-1 when RBD is in the up or down conformation.</p>
</caption>
<graphic xlink:href="EMS141212-f001"/>
</fig>
<fig id="F2" position="float">
<label>Figure 2</label>
<caption>
<title>SARS-CoV-2 monoclonal antibody binding and neutralization.</title>
<p>A. Models of SARS-CoV-2 WA-1 spike protein (PDB: 6XM3) with the locations of substitutions present of variants indicate as red dots. Also noted is the total number of mutation and the number and locations of receptor binding domain (RBD) mutants in variant of concern spike proteins.</p>
<p>B. Full length spike proteins from the indicated SARS-CoV-2 variants were expressed on the surface of transiently transfected 293T cells and binding to indicated monoclonal antibodies was assessed by flow cytometry. Shown is the mean fluorescence intensity (MFI) of bound antibody on the indicated cell relative to the MFI of the same antibody bound to D614G expressing cells. The data is expressed as a percentage. Shown is a representative experiment (n=2-3 for each antibody).</p>
<p>C. Lentiviruses pseudotyped with SARS-CoV-2 spike proteins from D614G, B.1.1.7, B.1.351, P.1, B.1.617.2 or B.1.1.529 were incubated with serial dilutions of the indicated antibodies and IC<sub>50</sub> and IC<sub>80</sub> values determined. S309 was tested on 293 flpin-TMPRSS2-ACE2 cells while all the other antibodies were tested on 293T-ACE2 cells. Ranges are indicated with white (&gt;10,000 ng/ml), light blue (&gt;1000 to ≤10,000 ng/ml), yellow (&gt;100 to ≤1000 ng/ml), orange (&gt;50 to ≤100 ng/ml), red (&gt;10 to ≤50 ng/ml), maroon (&gt;1 to ≤10 ng/ml), and purple (≤1 ng/ml). *n.d.= not determined due to incomplete neutralization that plateaued at &lt;80% (See <xref ref-type="supplementary-material" rid="SD1">Fig S4B</xref>).</p>
</caption>
<graphic xlink:href="EMS141212-f002"/>
</fig>
<fig id="F3" position="float">
<label>Figure 3</label>
<caption>
<title>Functional and structural basis of Class I antibody neutralization and mechanistic basis of retained potency against B.1.1.529 VOC.</title>
<p>A. Lentiviruses pseudotyped with SARS-CoV-2 spike proteins from D614G or D614G plus the indicated point mutations found within the B.1.1.529 spike were incubated with serial dilutions of the indicated antibodies, transduced 293T-ACE2 cells and IC<sub>50</sub> and IC<sub>80</sub> values determined. S375F and G496S viruses were not available and are shown as “not tested” (n.t.). G496R was available and substituted for G496S. Ranges are indicated with white (&gt;10,000 ng/ml), light blue (&gt;1000 to ≤10,000 ng/ml), yellow (&gt;100 to ≤1000 ng/ml), orange (&gt;50 to ≤100 ng/ml), red (&gt;10 to ≤50 ng/ml), maroon (&gt;1 to ≤10 ng/ml), and purple (≤1 ng/ml).</p>
<p>B. Mapping of B.1.1.529 amino acid substitutions at the epitope of Class I antibody CB6. RBD-bound CB6 was docked onto the B.1.1.529 spike structure. B.1.1.529 amino acid substitutions incompatible with CB6 binding were identified and labeled. K417N mutation caused clash in the center of the paratope. B.1.1.529 RBD is shown in green cartoon with amino acid substitutions in red sticks. CB6 is shown in surface representation with heavy and light chains colored yellow and slate, respectively.</p>
<p>C. Docking of RBD-bound VH1-58-derived Class I antibody B1-182.1 onto the B.1.1.529 spike structure identified 4 substitutions with potential steric hindrance. B1-182 is shown in surface representation with heavy and light chains colored olive and light blue. B.1.1.529 amino acid substitutions that may affect binding of VH1-58 antibodies were labeled.</p>
<p>D. Structural basis for effective neutralization of the B.1.1.529 VOC by VH1-58-derived antibodies. Even though VH1-58 antibodies, such as the S2E12, COV2-2196, A23-58.1 and B1-182.1, share high sequence homology (right, top), their neutralization potency against B.1.1.529 vary. Structural analysis indicated that CDR H3 residue 100C, located at the interfacial cavity formed by RBD, heavy and light chains, may determine their potency against B.1.1.529 (left). Size of this residue correlated with potency with two-tailed <italic>p</italic>=0.046 (right, bottom).</p>
</caption>
<graphic xlink:href="EMS141212-f003"/>
</fig>
<fig id="F4" position="float">
<label>Figure 4</label>
<caption>
<title>Functional and structural basis of Class II antibody binding, neutralization, and escape.</title>
<p>A. Lentiviruses pseudotyped with SARS-CoV-2 spike proteins from D614G or D614G plus the indicated point mutations found within the B.1.1.529 spike were incubated with serial dilutions of the indicated antibodies, transduced 293T-ACE2 cells and IC<sub>50</sub> and IC<sub>80</sub> values determined. S375F and G496S viruses were not available and are shown as “not tested” (n.t.). G496R was available and substituted for G496S. Ranges are indicated with white (&gt;10,000 ng/ml), light blue (&gt;1000 to ≤10,000 ng/ml), yellow (&gt;100 to ≤1000 ng/ml), orange (&gt;50 to ≤100 ng/ml), red (&gt;10 to ≤50 ng/ml), maroon (&gt;1 to ≤10 ng/ml), and purple (≤1 ng/ml).</p>
<p>B. Cryo-EM structure of class II antibody A19-46.1 Fab in complex with the B.1.1.529 spike. Overall density map is shown to the left with protomers colored light green, gray and light cyan. Two A19-46.1 Fabs bound to the RBD in the up-conformation are shown in orange and slate. Structure of the RBD and A19-46.1 after local focused refinement was shown to the right in cartoon representation. The heavy chain CDRs are colored brown, pink and orange for CDR H1, CDR H2 and CDR H3, respectively. The light chain CDRs are colored marine purple blue, marine blue and blue for CDR L1, CDR L2 and CDR L3, respectively. The contour level of Cryo-EM map is 4.0 s.</p>
<p>C. Interaction between A19-46.1 and RBD. CDR H3 and all light chain CDRs were involved in binding of RBD (left). Epitope of A19-46.1 is shown in orange on the green B.1.1.529 RBD surface with amino acid substitutions colored red. Ser446, A484 and R493 are located at the edge of the epitope of Fab A19-46.1 (right). RBD residues are labeled with italicized font.</p>
<p>D. Binding of A19-46.1 to RDB prevents binding of the ACE2 receptor. ACE2 and A19-46.1 are shown in cartoon representation.</p>
<p>E. Comparison of binding modes to RBD for antibody A19-46.1 and LY-CoV555. Even though both antibodies target similar regions on RBD, different approaching angle caused clash between LY-CoV555 CDR H3 and B.1.1.529 mutation Arg493 (left and inset). B.1.1.529 mutations involved in binding of A19-46.1 are only at the edge of its epitope while both Arg493 and A484 locate in the middle of LY-CoV555 epitope (right). Leu452 to Arg mutation that knockouts A19-46.1 and LY-CoV555 binding in other SARS-CoV-2 variants is colored in blue.</p>
</caption>
<graphic xlink:href="EMS141212-f004"/>
</fig>
<fig id="F5" position="float">
<label>Figure 5</label>
<caption>
<title>Functional and structural basis of Class III antibody binding, neutralization, and retained potency against the B.1.1.529 VOC.</title>
<p>A. Lentiviruses pseudotyped with SARS-CoV-2 spike proteins from D614G or D614G plus the indicated point mutations found within the B.1.1.529 spike were incubated with serial dilutions of the indicated antibodies and IC<sub>50</sub> and IC<sub>80</sub> values determined. A19-61.1 and LY-COV1404 were assayed on 293T-ACE2 cells while S309 and CoV2-2130 were tested on 293 flpin-TMPRSS2-ACE2 cells. S375F and G496S viruses were not available and are shown as “not tested” (n.t.). G496R was available and substituted for G496S. Ranges are indicated with white (&gt;10,000 ng/ml), light blue (&gt;1000 to ≤10,000 ng/ml), yellow (&gt;100 to ≤1000 ng/ml), orange (&gt;50 to ≤100 ng/ml), red (&gt;10 to ≤50 ng/ml), maroon (&gt;1 to ≤10 ng/ml), and purple (≤1 ng/ml).</p>
<p>B. Cryo-EM structure of SARS-CoV-2 WA-1 spike in complex with class I antibody B1-182.1 and class III antibody A19-61.1 at 2.83 Å resolution. Overall density map is shown with protomers colored light green, gray and wheat. Two RBDs were in the up conformation with each binding both Fabs, and one RBD was in the down position with A19-61.1 bound. RBD, B1-182.1 and A19-61.1 are colored olive and cyan, respectively (left). Structure of the RBD with both Fabs bound after local focused refinement was shown to the right in cartoon representation. RBD is shown in green cartoon and antibody light chains are colored light blue (middle). Epitope of A19-61.1 is shown as cyan colored surface on RBD with interacting CDRs labeled (right). The contour level of cryo-EM map is 5.2s.</p>
<p>C. Structural basis of B.1.1.529 resistance to A19-61.1. Mapping of the A19-61.1 epitope onto the B.1.1.529 RBD indicated G446S clashed with CDR H3 of A19-61.1. RBD is shown in green cartoon with mutation residues in red sticks, epitope of A19-61.1 is shown in cyan surface.</p>
<p>D. Structural basis of CoV2-2130 neutralization of the B.1.1.529 VOC. Docking of the CoV2-2130 onto the B.1.1.529 RBD showed Y50 in CDR L2 posed a minor clash with S446. RBD is shown in green cartoon with mutation residues in red sticks, epitope of CoV2-2130 is shown in pink surface.</p>
<p>E. Structural basis of S309 neutralization of the B.1.1.529 VOC. Docked complex of S309 and B.1.1.529 RBD showed the S371L/S373P/S375F. Loop. Changed conformation, and the S371L mutation is adjacent to S309 epitope while G339D mutation located inside the epitope. D339 sidechain clash with CDR H3 Y100. B.1.1.529 RBD is shown in green cartoon with mutation residues in red sticks, WA-1 RBD is shown in gray cartoon.</p>
<p>F. Structural basis of LY-CoV1404 neutralization of the B.1.1.529 VOC. Docking of the LY-CoV1404 onto the B.1.1.529 RBD identified 4 amino acid substitutions in the epitope with G446S causing potential clash with CDR H2 R60. However, comparison of both LY-CoV1404-bound and non-bound B.1.1.529 RBD indicated the S446 loop has the flexibility to allow LY-CoV1404 binding. B.1.1.529 residues at LY-CoV1404 epitope are shown as red sticks with corresponding WA-1 residues as green. sticks. CDR H3 is shown in cartoon representation and colored magenta.</p>
<p>G. Overlay of epitope footprints of class III antibodies onto the B.1.1.529 RBD. B.1.1.529 RBD amino acid substitution locations are colored red on green surface.</p>
</caption>
<graphic xlink:href="EMS141212-f005"/>
</fig>
<fig id="F6" position="float">
<label>Figure 6</label>
<caption>
<title>Potent neutralization of SARS-CoV-2 B.1.1.529 using combinations of antibodies.</title>
<p>A. Lentiviruses pseudotyped with SARS-CoV-2 spike proteins from D614G or D614G plus the indicated point mutations found within the B.1.1.529 spike were incubated with serial dilutions of the indicated combination of antibodies and IC<sub>50</sub> and IC<sub>80</sub> values determined. S375F and G496S viruses were not available and are shown as “not tested” (n.t.). G496R was available and substituted for G496S. Ranges are indicated with white (&gt;10,000 ng/ml), light blue (&gt;1000 to ≤10,000 ng/ml), yellow (&gt;100 to ≤1000 ng/ml), orange (&gt;50 to ≤100 ng/ml), red (&gt;10 to ≤50 ng/ml), maroon (&gt;1 to ≤10 ng/ml), and purple (≤1 ng/ml).</p>
<p>B. Neutralization IC<sub>50</sub> (ng/mL) values for each of the indicated cocktail (x-axis) or its component antibodies. The IC<sub>50</sub> for first antibody is listed as mAb1 (black), the second antibody as mAb2 (grey) or cocktail (red).</p>
<p>C. Cryo-EM structure of B.1.1.529 spike in complex with antibodies A19-46.1 and B-182.1 at 3.86 Å resolution. Overall density map is shown to the left with protomers colored light green, wheat and light cyan (left). All RBD are in up-conformation with both Fabs bound (middle). Binding of one Fab (such as B1-182.1) induces RBD into the up-conformation and potentially facilitates binding of the other Fab (such as A19-46.1) which only recognizes the up-conformation of RBD (right). A19-46.1 and B-182.1 are shown in orange and olive color, respectively. The contour level of cryo-EM map is 6.5 s.</p>
</caption>
<graphic xlink:href="EMS141212-f006"/>
</fig>
</floats-group>
</article>
